Abstract
The pharmaceutical industry struggles with increasing costs to confidently validate drug targets and develop optimized drug molecules that successfully and safely translate efficacy into the clinic. Clinical prediction of success is imperative to reduce and recoup the costs associated with drug development. Strategies to enable clinical prediction rely on new technologies that can be employed earlier in the drug discovery process. In vivo imaging technologies, such as MRI, PET, SPECT, CT, and optical, are being employed exponentially to almost every aspect of the drug discovery process for earlier assessments. Quantitative imaging approaches for assessing disease end points are required to provide the precision to understand the efficacy and toxicity of new medicines rather than relying on blunt measures of clinical scoring. The bidirectional translation of preclinical and clinical drugs and drug assessments has provided new insights into the profiles of disease and toxicity rather than “snapshots” of pathology that occur using conventional ex vivo techniques. MRI technology has developed significantly over the last 20 years with respect to speed of acquisition, higher resolutions, and better tissue contrast imaging techniques. MRI enables new image-based evidence to successfully translate new chemical entities into clinical practice. This imaging technique provides a means to quantify disease and detect unprecedented rare and common disease mechanisms, which enables new medicines to be developed that can improve the quality of human life.
Similar content being viewed by others
References
DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419–31.
Contag PR. Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov Today. 2002;7(10):555–62.
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.
Beam TR, Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis. 1992;15(Supplement 1):S5–S32.
Lu Z-R. Application of biomedical imaging in drug discovery and development. Pharm Res. 2007;24(6):1170–1.
Epstein FH. MR in mouse models of cardiac disease. NMR Biomed. 2007;20(3):238–55.
Rudin M. Imaging in drug discovery and early clinical trials. New York: Springer Science & Business Media; 2005.
Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, et al. Combined PET/CT imaging in oncology: impact on patient management. Clin Positron Imaging. 2000;3(6):223–30.
Meikle SR, Beekman FJ, Rose SE. Complementary molecular imaging technologies: high resolution SPECT, PET and MRI. Drug Discov Today Technol. 2006;3(2):187–94.
Atkinson DJ, Edelman R. Cineangiography of the heart in a single breath hold with a segmented turboFLASH sequence. Radiology. 1991;178(2):357–60.
O’Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96(2):189–95.
Golman K, Petersson JS. Metabolic imaging and other applications of hyperpolarized 13 C 1. Acad Radiol. 2006;13(8):932–42.
Möller HE, Chen XJ, Saam B, Hagspiel KD, Johnson GA, Altes TA, et al. MRI of the lungs using hyperpolarized noble gases. Magn Reson Med. 2002;47(6):1029–51.
Beckmann N, Cannet C, Karmouty-Quintana H, Tigani B, Zurbruegg S, Blé F-X, et al. Lung MRI for experimental drug research. Eur J Radiol. 2007;64(3):381–96.
Sobol WT. Recent advances in MRI technology: implications for image quality and patient safety. Saudi J Ophthalmol. 2012;26(4):393–9.
Thompson A, Montalban X, Barkhof F, Brochet B, Filippi M, Miller D, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47(6):831–5.
Dean DG. The role of MRI in musculoskeletal practice: a clinical perspective. J Man Manip Ther. 2011;19(3):152–61.
Neubauer S, Beer M, Landschütz W, Sandstede J, Seyfarth T, Lipke C, et al. Absolute quantification of high energy phosphate metabolites in normal, hypertrophied and failing human myocardium. MAGMA. 2000;11(1–2):73–4.
Cosmus TC, Parizh M. Advances in whole-body MRI magnets. IEEE Trans Appl Supercond. 2011;21(3):2104–9.
Lemieux L, Hagemann G, Krakow K, Woermann FG. Fast, accurate, and reproducible automatic segmentation of the brain in T1-weighted volume MRI data. Magn Reson Med. 1999;42(1):127–35.
Miller D, Rudge P, Johnson G, Kendall B, Macmanus D, Moseley I, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988;111(4):927–39.
Group IMSS. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–61.
Raynauld J-P, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009;68(6):938–47.
Wullschleger S, Garcia-Martinez JM, Duce SL. Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma. Anticancer Res. 2012;32(2):415–20.
Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med. 1994;32(6):749–63.
Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol. 2009;66(6):714–20.
Mosher TJ, Dardzinski BJ, editors. Cartilage MRI T2 relaxation time mapping: overview and applications. Semin Musculoskelet Radiol. 2004;8:355–68. Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001 USA.
Cheng HLM, Wright GA. Rapid high-resolution T1 mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med. 2006;55(3):566–74.
Mikac U, Sepe A, Kristl J, Baumgartner S. A new approach combining different MRI methods to provide detailed view on swelling dynamics of xanthan tablets influencing drug release at different pH and ionic strength. J Control Release. 2010;145(3):247–56.
Detre JA, Zhang W, Roberts DA, Silva AC, Williams DS, Grandis DJ, et al. Tissue specific perfusion imaging using arterial spin labeling. NMR Biomed. 1994;7(1–2):75–82.
Østergaard L. Principles of cerebral perfusion imaging by bolus tracking. J Magn Reson Imaging. 2005;22(6):710–7.
Geraldes CF, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging. 2009;4(1):1–23.
Paldino MJ, Barboriak DP. Fundamentals of quantitative dynamic contrast-enhanced MR imaging. Magn Reson Imaging Clin N Am. 2009;17(2):277–89.
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223–32.
Parker GJ, Tofts PS. Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. Top Magn Reson Imaging. 1999;10(2):130–42.
Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Fundamental concepts. Magn Reson Med. 1991;17(2):357–67.
Backhaus M, Kamradt T, Sandrock D, Loreck D, Fritz J, Wolf K, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42(6):1232–45.
Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002;15(1):62–7.
Low RN, Francis IR, Politoske D, Bennett M. Crohn’s disease evaluation: comparison of contrast-enhanced MR imaging and single-phase helical CT scanning. J Magn Reson Imaging. 2000;11(2):127–35.
Roberts C, Issa B, Stone A, Jackson A, Waterton JC, Parker GJ. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging. 2006;23(4):554–63.
Sinkus R, Van Beers BE, Vilgrain V, DeSouza N, Waterton JC. Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. Eur J Cancer. 2012;48(4):425–31.
Tatlisumak T, Carano RA, Takano K, Opgenorth TJ, Sotak CH, Fisher M. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion a diffusion and perfusion MRI study. Stroke. 1998;29(4):850–8.
Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001;61(13):4971–3.
Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47(4):462–9.
Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161(2):401–7.
Koh D-M, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. Am J Roentgenol. 2011;196(6):1351–61.
Burdette JH, Elster AD, Ricci PE. Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology. 1999;212(2):333–9.
Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014;272(2):417–26.
Larsson HB, Rosenbaum S, Fritz-Hansen T. Quantification of the effect of water exchange in dynamic contrast MRI perfusion measurements in the brain and heart. Magn Reson Med. 2001;46(2):272–81.
Dalvit C, Pevarello P, Tatò M, Veronesi M, Vulpetti A, Sundström M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR. 2000;18(1):65–8.
Pellecchia M, Sem DS, Wüthrich K. NMR in drug discovery. Nat Rev Drug Discov. 2002;1(3):211–9.
Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med. 1989;10(1):135–44.
Schmitt B, Zbýň Š, Stelzeneder D, Jellus V, Paul D, Lauer L, et al. Cartilage quality assessment by using glycosaminoglycan chemical exchange saturation transfer and 23Na MR imaging at 7 T. Radiology. 2011;260(1):257–64.
Abramson SB, Attur M, Yazici Y. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol. 2006;2(6):304–12.
Weissleder R, Cheng HC, Bogdanova A, Bogdanov A. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging. 1997;7(1):258–63.
Wang Y-XJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11(11):2319–31.
Weissleder R, Elizondo G, Wittenberg J, Rabito C, Bengele H, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990;175(2):489–93.
Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. Am J Neuroradiol. 2002;23(4):510–9.
Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13(6):1266–76.
Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011;1(1):35–40.
McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von zur Muhlen C, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008;28(1):77–83.
Lanza GM, Lorenz CH, Fischer SE, Scott MJ, Cacheris WP, Kaufmann RJ, et al. Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. Acad Radiol. 1998;5:S173–S6.
Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004;109(16):2023–9.
Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with αvβ3-integrin–targeted nanoparticles. Circulation. 2003;108(18):2270–4.
Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li K. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4(5):623–6.
Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, et al. Magnetic resonance contrast enhancement of neovasculature with αvβ3-targeted nanoparticles. Magn Reson Med. 2000;44(3):433–9.
Beckmann N, Mueggler T, Allegrini PR, Laurent D, Rudin M. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat Rec. 2001;265(2):85–100.
McAteer MA, Akhtar AM, von zur Muhlen C, Choudhury RP. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis. 2010;209(1):18–27.
McAteer MA, Mankia K, Ruparelia N, Jefferson A, Nugent HB, Stork L-A, et al. A leukocyte-mimetic magnetic resonance imaging contrast agent homes rapidly to activated endothelium and tracks with atherosclerotic lesion macrophage content. Arterioscler Thromb Vasc Biol. 2012;32(6):1427–35.
McAteer MA, Choudhury RP. Targeted molecular imaging of vascular inflammation in cardiovascular disease using nano- and micro-sized agents. Vascul Pharmacol. 2013;58(1):31–8.
Bergin C, Pauly J, Macovski A. Lung parenchyma: projection reconstruction MR imaging. Radiology. 1991;179(3):777–81.
Gold GE, Thedens DR, Pauly JM, Fechner K, Bergman G, Beaulieu CF, et al. MR imaging of articular cartilage of the knee: new methods using ultrashort TEs. AJR Am J Roentgenol. 1998;170(5):1223–6.
Weiger M, Pruessmann KP, Hennel F. MRI with zero echo time: hard versus sweep pulse excitation. Magn Reson Med. 2011;66(2):379–89.
Ahn C, Kim J, Cho Z. High-speed spiral-scan echo planar NMR imaging-I. IEEE Trans Med Imaging. 1986;5(1):2–7.
Irarrazabal P, Nishimura DG. Fast three dimensional magnetic resonance imaging. Magn Reson Med. 1995;33(5):656–62.
Nielles-Vallespin S, Weber M-A, Bock M, Bongers A, Speier P, Combs SE, et al. 3D radial projection technique with ultrashort echo times for sodium MRI: clinical applications in human brain and skeletal muscle. Magn Reson Med. 2007;57(1):74–81.
Beckmann N, Tigani B, Mazzoni L, Fozard JR. Techniques: magnetic resonance imaging of the lung provides potential for non-invasive preclinical evaluation of drugs. Trends Pharmacol Sci. 2003;24(10):550–4.
Takahashi M, Togao O, Obara M, van Cauteren M, Ohno Y, Kuro-O M, et al. Ultra-short echo time (UTE) MR imaging of the lung: comparison between normal and emphysematous lungs in mutant mice. J Magn Reson Imaging. 2010;32(2):326–33.
Strobel K, Hoerr V, Schmid F, Wachsmuth L, Löffler B, Faber C. Early detection of lung inflammation: exploiting T1-effects of iron oxide particles using UTE MRI. Magn Reson Med. 2012;68(6):1924–31.
Mentore K, Froh DK, de Lange EE, Brookeman JR, Paget-Brown AO, Altes TA. Hyperpolarized He 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. Acad Radiol. 2005;12(11):1423–9.
Bianchi A, Ozier A, Ousova O, Raffard G, Crémillieux Y. Ultrashort-TE MRI longitudinal study and characterization of a chronic model of asthma in mice: inflammation and bronchial remodeling assessment. NMR Biomed. 2013;26(11):1451–9.
Bianchi MC, Tosetti M, Battini R, Manca ML, Mancuso M, Cioni G, et al. Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. Am J Neuroradiol. 2003;24(10):1958–66.
Rajagopalan B, Blackledge M, McKenna W, Bolas N, Radda G. Measurement of phosphocreatine to ATP ratio in normal and diseased human heart by 31P magnetic resonance spectroscopy using the rotating frame-depth selection techniques. Ann N Y Acad Sci. 1987;508(1):321–32.
Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed. 2004;17(1):10–20.
Hoang T, Bluml S, Dubowitz D, Moats R, Kopyov O, Jacques D, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington’s and Parkinson’s diseases. Neurology. 1998;50(4):1033–40.
Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96(7):2190–6.
Gupta R, Pandey R, Khan E, Mittal P, Gujral R, Chhabra D. Intracranial tuberculomas: MRI signal intensity correlation with histopathology and localised proton spectroscopy. Magn Reson Imaging. 1993;11(3):443–9.
Yeung DK, Yang W-T, Tse GM. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases 1. Radiology. 2002;225(1):190–7.
Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent implications for rational therapy of restenosis. Circulation. 2002;106(22):2842–7.
Berglund M, Wieser ME. Isotopic compositions of the elements 2009 (IUPAC technical report). Pure Appl Chem. 2011;83(2):397–410.
Walker TG, Happer W. Spin-exchange optical pumping of noble-gas nuclei. Rev Mod Phys. 1997;69(2):629.
Appelt S, Baranga AB-A, Erickson C, Romalis M, Young A, Happer W. Theory of spin-exchange optical pumping of 3 He and 129 Xe. Phys Rev A. 1998;58(2):1412.
Hausser K, Stehlik D. Dynamic nuclear polarization in liquids. Adv Magn Reson. 1968;3:79–139.
McCarney ER, Armstrong BD, Lingwood MD, Han S. Hyperpolarized water as an authentic magnetic resonance imaging contrast agent. Proc Natl Acad Sci. 2007;104(6):1754–9.
Rzedzian R, Mansfield P, Doyle M, Guilfoyle D, Chapman B, Coupland R, et al. Real-time nuclear magnetic resonance clinical imaging in paediatrics. Lancet. 1983;322(8362):1281–2.
Glöggler S, Raue M, Colell J, Türschmann P, Liebisch A, Mang T, et al. Online monitoring of intelligent polymers for drug release with hyperpolarized xenon. ChemPhysChem. 2012;13(18):4120–3.
Edwards R, Wilkie D, Dawson MJ, Gordon R, Shaw D. Clinical use of nuclear magnetic resonance in the investigation of myopathy. Lancet. 1982;319(8274):725–31.
Bottomley PA, Hardy CJ, Roemer PB, Mueller OM. Proton-decoupled, overhauser-enhanced, spatially localized carbon-13 spectroscopy in humans. Magn Reson Med. 1989;12(3):348–63.
Khemtong C, Carpenter NR, Lumata LL, Merritt ME, Moreno KX, Kovacs Z, et al. Hyperpolarized 13C NMR detects rapid drug-induced changes in cardiac metabolism. Magn Reson Med. 2015;74(2):312–9.
Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC, Group. A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology. 2011;258(3):906–14.
Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015;17(9):1188–98.
Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1–12.
McGibney G, Smith M, Nichols S, Crawley A. Quantitative evaluation of several partial fourier reconstruction algorithms used in MRI. Magn Reson Med. 1993;30(1):51–9.
McKenzie CA, Yeh EN, Ohliger MA, Price MD, Sodickson DK. Self-calibrating parallel imaging with automatic coil sensitivity extraction. Magn Reson Med. 2002;47(3):529–38.
Lustig M, Donoho DL, Santos JM, Pauly JM. Compressed sensing MRI. IEEE Signal Process Mag. 2008;25(2):72–82.
Lustig M, Donoho D, Pauly JM. Sparse MRI: the application of compressed sensing for rapid MR imaging. Magn Reson Med. 2007;58(6):1182–95.
Cheng JY, Hanneman K, Zhang T, Alley MT, Lai P, Tamir JI, et al. Comprehensive motion-compensated highly accelerated 4D flow MRI with ferumoxytol enhancement for pediatric congenital heart disease. J Magn Reson Imaging. 2016;43(6):1355–68.
Misiak M, Koźmiński W, Chmurski K, Kazimierczuk K. Study of near-symmetric cyclodextrins by compressed sensing 2D NMR. Magn Reson Chem. 2013;51(2):110–5.
Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3(12):1023–35.
Ma D, Gulani V, Seiberlich N, Liu K, Sunshine JL, Duerk JL, et al. Magnetic resonance fingerprinting. Nature. 2013;495(7440):187–92.
Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol. 2000;40(8):803–14.
(ESR) ESoR. Magnetic Resonance Fingerprinting – a promising new approach to obtain standardized imaging biomarkers from MRI. Insights Imaging. 2015;6(2):163–5.
Freeborough PA, Fox NC. MR image texture analysis applied to the diagnosis and tracking of Alzheimer’s disease. IEEE Trans Med Imaging. 1998;17(3):475–8.
Sutton RN, Hall EL. Texture measures for automatic classification of pulmonary disease. IEEE Trans Comput. 1972;21(7):667–76.
Kjaer L, Ring P, Thomsen C, Henriksen O. Texture analysis in quantitative MR imaging: tissue characterisation of normal brain and intracranial tumours at 1.5 T. Acta Radiol. 1995;36(2):127–35.
Chen G, Jespersen S, Pedersen M, Pang Q, Horsman MR, Stødkilde JH. Evaluation of anti-vascular therapy with texture analysis. Anticancer Res. 2005;25(5):3399–405.
Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261(1):165–71.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Kaggie, J.D., Haase, M.V., Campbell, S.P., Wright, C.M., Graves, M.J., Changani, K.K. (2017). Role of Magnetic Resonance in Drug Development. In: Webb, G. (eds) Modern Magnetic Resonance. Springer, Cham. https://doi.org/10.1007/978-3-319-28275-6_101-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-28275-6_101-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28275-6
Online ISBN: 978-3-319-28275-6
eBook Packages: Springer Reference Chemistry and Mat. ScienceReference Module Physical and Materials ScienceReference Module Chemistry, Materials and Physics